Russ Conroy is an Assistant Editor for CancerNetwork. He specializes in medicine and healthcare, focusing on topics such as oncology, hematology, immunotherapy, and medical technology innovations. Russ's work has been featured in prominent publications including AJMC - The American Journal of Managed Care, Dermatology Times, and Oncology Nursing News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Russ Conroy's articles primarily focus on healthcare and pharmaceutical topics, with a significant emphasis on citing data to support the information provided. Given this approach, Russ would likely be interested in pitches that provide access to new or exclusive scientific research findings related to cancer treatment, leukemia, breast cancer, multiple myeloma, and immunotherapy.
Since Russ focuses heavily on citing data and presenting evidence-based information in his articles, he may be particularly responsive to pitches from experts who can provide insights based on the latest clinical trials or research studies within the field of oncology and cancer treatment. Additionally, sources who can offer contextualized expert commentary supported by robust scientific evidence could capture his interest.
While there is no specific geographic focus mentioned for Russ Conroy’s coverage attributes or article titles provided here; it appears that he covers a broad range of international developments in healthcare and pharmaceuticals without being limited to any particular region.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Data from studies including the IRAKLIA trial support the approval of subcutaneous isatuximab plus standard of care in multiple myeloma.
The FDA has assigned a Prescription Drug User Fee Act date of May 13, 2027, for the mezigdomide regimen in relapsed/refractory multiple myeloma.
By: Russ Conroy
Mature overall survival data from the INSIGHT-003 trial compare favorably with historical benchmarks in frontline NSCLC therapy.
By: Russ Conroy
The world of cellular therapy is “still ever-expanding” as novel constructs continue to emerge, according to Megan Melody, MD.
By: Russ Conroy
Experts discuss how to properly select first-line regimens for EGFR-mutated NSCLC in the context of different clinical scenarios.
Approval of the SimpleScreen CRC test may increase earlier detection of colorectal cancer and improve patient outcomes.
Clinicians “still don't have the answer” on true toxicity thresholds, says Tiba Al Sagheer, PharmD, BCOP, BCACP, on CAR T-cell toxicity management.
Phase 1 trial data for cevostamab in multiple myeloma validate fixed-duration therapy as a “good concept,” according to Adam D. Cohen, MD.
The approval status of lurbinectedin as first-line care for those with small cell lung cancer will not be impacted following results from the LAGOON trial.
Ajay K. Nooka, MD, MPH, FACP, discusses how results from the MonumenTAL-6 trial build upon prior studies assessing bispecific antibodies in multiple myeloma.
